Litigation Details for Pfizer Inc. v. Aurobindo Pharma Ltd. (D. Del. 2014)

Pfizer Inc. v. Aurobindo Pharma Ltd. (D. Del. 2014)

Docket		Date Filed	2014-07-02
Court	District Court, D. Delaware	Date Terminated	2015-09-22
Cause	35:0145	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Patents	7,879,828; 8,372,995
Link to Docket	External link to docket

Details for Pfizer Inc. v. Aurobindo Pharma Ltd. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-02				External link to document

Litigation summary and analysis for: Pfizer Inc. v. Aurobindo Pharma Ltd. (D. Del. 2014)

Last updated: July 30, 2026

Pfizer Inc. v. Aurobindo Pharma Ltd. (1:14-cv-00872): Litigation Summary, Claims at Issue, and Patent/Regulatory Risk Analysis

Executive summary

Pfizer’s case against Aurobindo Pharma in 1:14-cv-00872 is a U.S. patent infringement dispute tied to an FDA generic approval pathway, with the litigation centered on Orange Book-listed patents for Pfizer’s branded product and Aurobindo’s proposed generic entry. The dispute proceeds under the Hatch-Waxman framework using Paragraph IV allegations, where Pfizer’s asserted patents are the key determinants of (1) whether Aurobindo can market immediately on FDA approval and (2) the timing and scope of any settlement or design-around outcomes.

This matter’s business relevance is concentrated in three zones:

1. Which patents were asserted and what claims (composition, method, formulation, or use) those patents cover.
2. Whether the court addressed validity and infringement and how that impacts Aurobindo’s launch freedom for specific claims.
3. How the outcome changes the exclusivity/market entry risk for other generic entrants using the same reference listed drug (RLD) and similar ANDA strategies.

What patent estate and Orange Book patents are at issue in Pfizer v. Aurobindo (1:14-cv-00872)?

Featured-snippet answer: The litigation tests Aurobindo’s Paragraph IV position on Pfizer’s Orange Book-listed patents for the applicable Pfizer branded drug, including patents that typically fall into composition of matter, formulation, and/or method-of-use categories, depending on the RLD and listed protections.

What makes this case a Hatch-Waxman dispute

Paragraph IV litigation under 21 U.S.C. § 355(j)(2)(A) usually turns on:

• the listed patent numbers in the Orange Book for the Pfizer drug at filing, and
• Aurobindo’s ANDA certification(s) and corresponding challenges (non-infringement, invalidity, or both).

The case number format indicates a federal district court action in 2014, consistent with an ANDA Paragraph IV round where FDA approval could be stayed pending litigation.

Patent categories commonly litigated in Pfizer vs. generic ANDA challengers

Even where courts differ in how they frame claims, generic-company infringement defenses usually track patent type:

• Composition-of-matter: challenges focus on novelty/non-obviousness and direct infringement
• Method-of-use: disputes focus on practicing claimed dosing/regimens and induced infringement
• Formulation/process: disputes focus on structural or process differences between generic and patented embodiment

How the patent estate affects market entry

For ANDA challengers, the decisive factor is whether Pfizer’s asserted patents survive both infringement and validity. If any asserted patent is upheld, the generic launch can be blocked by the statutory scheme until expiration or a successful carve-out.

---

How strong is Pfizer’s patent case versus Aurobindo in 1:14-cv-00872?

Featured-snippet answer: Strength tracks to the survival rate of the asserted patents through claim construction, dispositive rulings, and final judgment, and to whether Aurobindo was able to narrow the case through design-around or non-infringement proof.

Key litigation steps that determine strength

1. Claim construction: court interpretation defines the infringement boundary.
2. Infringement analysis: compares accused generic product/process with claim elements.
3. Validity challenges: often a mix of obviousness, anticipation, and lack of enablement written-description issues.

Business interpretation

• If Pfizer prevailed on infringement but lost validity, Aurobindo can sometimes design around or pursue a different approval path.
• If Pfizer lost infringement, Aurobindo can face fewer constraints for launch.
• If Aurobindo loses validity or infringement across all asserted patents, the market entry timeline shifts.

---

When does Pfizer’s exclusivity block Aurobindo launch in this case? What are the timing risks?

Featured-snippet answer: Timing risk hinges on (i) the statutory 30-month stay triggered by Paragraph IV, and (ii) the expiration dates and remaining terms of Pfizer’s asserted Orange Book patents.

Hatch-Waxman timing mechanics

• Filing of an ANDA with a Paragraph IV certification triggers an automatic 30-month stay under 21 U.S.C. § 355(j)(5)(B) unless an earlier court decision shortens it.
• If the court enters an infringement judgment for Pfizer on an asserted patent, the generic launch is generally constrained until patent expiration or settlement.

Practical consequence for commercial planning

Even if FDA approval timing accelerates, launch is still gated by the surviving patent(s). For competitors, the question becomes whether the outcome creates:

• an early launch window,
• a delayed launch window with settlement terms, or
• a broader deterrent effect on other ANDA filers.

---

What generic entry risks exist for Aurobindo if Pfizer wins or loses on the asserted patents?

Featured-snippet answer: Aurobindo’s launch risk is binary at the patent level: a final judgment of infringement for at least one asserted patent generally blocks marketing until that patent’s term ends; a final judgment invalidating the asserted patents removes the primary barrier.

If Pfizer wins infringement

• Aurobindo’s marketing is blocked until expiration of the asserted patent(s) or successful appellate/settlement resolution.
• Aurobindo may seek carve-outs only if the court’s construction or claims allow it.

If Aurobindo wins invalidity or non-infringement

• Aurobindo’s launch can move forward if the win covers all asserted patents that block the ANDA path.
• Other ANDA filers can also benefit via shared patent rulings depending on the specific patents and product overlaps.

---

Did this litigation produce a settlement, licensing deal, or consent judgment?

Featured-snippet answer: Settlement outcomes in this class of cases typically take the form of (1) payment-for-delay or (2) an agreed launch date contingent on patent positions, or (3) non-monetary licensing/design-around agreements.

How to interpret settlement terms commercially

For investors and strategists, the decisive settlement data are:

• which patents are covered by the settlement,
• whether design-around is allowed,
• permitted launch timing,
• any injunction or carve-out scope,
• and any license duration or royalty triggers.

---

What is the Orange Book status of Pfizer’s drug referenced in 1:14-cv-00872?

Featured-snippet answer: The Orange Book lists the patents that Pfizer used to block FDA approval at the ANDA stage. The litigation focuses on those listed patents and their enforceability against Aurobindo’s proposed generic.

How Orange Book status maps to litigation

• Orange Book listing date and patent term dictate the remaining time at filing.
• Patent type dictates the likely defenses and whether the generic can design around.

What to watch for in Orange Book listings

• whether patents are composition vs. method vs. formulation,
• whether continuation patents are used to extend specific protection, and
• whether multiple patents were asserted simultaneously, which affects settlement leverage.

---

What court rulings and procedural outcomes shape the case’s outcome?

Featured-snippet answer: In ANDA Paragraph IV cases, court rulings that matter most are claim construction and dispositive decisions on infringement/validity that either support or remove the statutory launch bar.

Common procedural milestones

• scheduling orders
• Markman claim construction
• summary judgment motions
• expert report deadlines
• trial and final judgment or dismissal
• appellate posture if judgment is appealed

---

How does this Pfizer v. Aurobindo litigation compare with other Pfizer vs. generic patent fights?

Featured-snippet answer: The strategic structure is consistent with Pfizer’s broader enforcement posture: Pfizer sues the Paragraph IV ANDA filer on Orange Book patents; the case outcome determines whether the generic entrant can market and whether other filers face copycat risk.

Comparison dimensions

• number of asserted patents
• patent types (composition vs. method vs. formulation)
• how quickly dispositive rulings land
• likelihood of settlement once claim construction narrows the infringement boundary
• potential design-around success based on formulation or method claims

---

Key takeaways

• The case (1:14-cv-00872) is structured as a Hatch-Waxman Paragraph IV infringement action where Pfizer’s Orange Book-listed patents define the core infringement and validity questions.
• Launch timing and commercial impact are driven by which asserted patents survive and the interplay with the 30-month stay and patent expiration.
• For Aurobindo and other ANDA strategists, the outcome defines whether the generic can enter immediately post-FDA approval or is constrained until specific patent term(s) end.

---

FAQs

1) What does “1:14-cv-00872” indicate for Hatch-Waxman timing?
It indicates a federal district court action filed in 2014, consistent with Paragraph IV ANDA enforcement timing that can trigger and govern a statutory stay.

2) Which types of patents are most commonly asserted in Pfizer generic litigation?
Composition-of-matter, formulation, and method-of-use patents are the dominant categories in Orange Book disputes.

3) How do Paragraph IV certifications impact court issues in these cases?
They require the ANDA filer to certify regarding Orange Book patents and formally contest one or more listed patents, which then becomes the case’s infringement and validity focus.

4) What determines whether Aurobindo can launch after a favorable FDA decision?
Whether any asserted Orange Book patent remains enforceable against the proposed generic product after the court’s final rulings or settlement.

5) Do outcomes in one Paragraph IV case affect other generic entrants?
Often, but the effect is patent-specific: other entrants may benefit from legal findings if they challenge the same patents for substantially similar products and claims.

---

References (APA)

1. Pfizer Inc. v. Aurobindo Pharma Ltd., No. 1:14-cv-00872 (D. ? 2014). (Court docket and filings, via PACER or RECAP).
2. 21 U.S.C. § 355(j)(5)(B).